MANNHEIM, Germany - There is not going to be a happy ending to the story for small biotech development companies moving forward into the continuing nightmare of the current financial crisis, according to the panel of high level investors and big pharma executives. (BioWorld International)

No Abstract BioWorld International CorrespondentGanymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications.